- Home
- CDTG vs SLGL Comparison
CDTG vs SLGL Comparison
Compare CDTG & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTG
- SLGL
- Stock Information
- Founded
- CDTG 2012
- SLGL 1997
- Country
- CDTG China
- SLGL Israel
- Employees
- CDTG N/A
- SLGL N/A
- Industry
- CDTG
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- CDTG
- SLGL Health Care
- Exchange
- CDTG NYSE
- SLGL Nasdaq
- Market Cap
- CDTG 24.5M
- SLGL 19.3M
- IPO Year
- CDTG 2024
- SLGL 2018
- Fundamental
- Price
- CDTG $0.69
- SLGL $8.14
- Analyst Decision
- CDTG
- SLGL Buy
- Analyst Count
- CDTG 0
- SLGL 1
- Target Price
- CDTG N/A
- SLGL $40.00
- AVG Volume (30 Days)
- CDTG 745.9K
- SLGL 25.4K
- Earning Date
- CDTG 05-15-2025
- SLGL 08-15-2025
- Dividend Yield
- CDTG N/A
- SLGL N/A
- EPS Growth
- CDTG N/A
- SLGL N/A
- EPS
- CDTG 0.14
- SLGL N/A
- Revenue
- CDTG $29,765,205.00
- SLGL $12,103,000.00
- Revenue This Year
- CDTG N/A
- SLGL N/A
- Revenue Next Year
- CDTG N/A
- SLGL $31.17
- P/E Ratio
- CDTG $5.19
- SLGL N/A
- Revenue Growth
- CDTG N/A
- SLGL 603.66
- 52 Week Low
- CDTG $0.52
- SLGL $3.34
- 52 Week High
- CDTG $4.64
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- CDTG N/A
- SLGL 63.80
- Support Level
- CDTG N/A
- SLGL $6.96
- Resistance Level
- CDTG N/A
- SLGL $7.48
- Average True Range (ATR)
- CDTG 0.00
- SLGL 0.28
- MACD
- CDTG 0.00
- SLGL 0.07
- Stochastic Oscillator
- CDTG 0.00
- SLGL 95.88
About CDTG CDT ENVIRONMENTAL TECH INV HLDG LTD
CDT Environmental Technology Investment Holdings Ltd is a waste treatment company. The company generates revenue through the design, development, manufacture, sales, installation, operation and maintenance of sewage treatment systems and by providing sewage treatment services. It engages in two business lines namely, rural sewage treatment and septic tank treatment in both urban and rural areas.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.